Leadership

Leadership

Sanjay Keswani, Chief Executive Officer 
Sanjay Keswani
Chief Executive Officer

Sanjay Keswani is CEO at Rheos Medicines and has nearly two decades of drug development leadership experience across multiple therapeutic areas. He joined Rheos from Roche where he was Senior Vice President and Global Head of Neuroscience, Ophthalmology and Rare diseases for Roche Pharma Research and Early Development. Prior to Roche, he was Vice President, Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He held R&D leadership roles at Eli Lily & Co. and Amgen, Inc. and also served as Assistant Professor in Neurology at The Johns Hopkins University. Dr. Keswani completed his medical residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at The Johns Hopkins University School of Medicine and his MBBS in medicine at St. Bartholomew’s Hospital, London. In addition, Dr. Keswani holds a first class honors degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology) and was recently elected as a Fellow of the Royal College of Physicians (FRCP).

Laurence Turka, MD, Chief Scientific Officer 
Laurence Turka, MD
Chief Scientific Officer

Company co-founder, Laurence Turka, MD, joins Rheos as Chief Scientific Officer, following a 30-year academic career as a transplant immunologist, most recently as the Harold and Ellen Danser Professor of Surgery and Professor of Medicine at Harvard Medical School and Massachusetts General Hospital.  Among the notable discoveries of Larry’s laboratory were novel approaches to transplantation tolerance, the role of Toll-like receptors in T-cells, and pathways required for the maintenance of regulatory T-cell function.  Larry was also an early contributor to the field of T-cell costimulation and helped contribute to the development of abatacept and belatacept for the treatment of rheumatoid arthritis and renal transplantation.

Larry received his MD degree from the Yale University School of Medicine, trained in Internal Medicine at Yale-New Haven Hospital and in Nephrology at the Brigham and Women’s Hospital/Harvard Medical School.  He is a former Chief of the Renal Division at the University of Pennsylvania, President of the American Society of Transplantation, Chair of the NIAID Board of Scientific Counselors, and Editor in Chief of The Journal of Clinical Investigation.  He currently serves as Deputy Director of the Immune Tolerance Network and is a Professor of Surgery and Medicine (part-time) at Harvard Medical School.  He was elected to membership in the American Society for Clinical Investigation in 1995, and the Association of American Physicians in 2003.

Gad Soffer, Chief Operating Officer  
Gad Soffer
Chief Operating Officer

Gad Soffer joins Rheos from Atara Biotherapeutics where he was Executive Vice President and Chief Strategy Officer. Prior to Atara, he worked at Celgene as Executive Director and Global Project Leader where he led the team responsible for product development and lifecycle management for Abraxane, a breast, lung, and pancreatic cancer treatment also in development for melanoma. He also served as Director of Business Development at Celgene where he led numerous business development transactions while advising on venture investment and strategic partnerships. Earlier, Mr. Soffer was a healthcare consultant with Easton Associates. He earned an M.B.A. at Harvard Business School, an M.S. at Columbia University and an A.B. from Harvard University.

Ryan Cohlhepp, PharmD, Senior Vice President, R&D Strategy & Operations 
Ryan Cohlhepp, PharmD
Senior Vice President, R&D Strategy & Operations

Ryan is currently the Senior Vice President of R&D Strategy and Operations for Rheos. Ryan recently transitioned from Takeda Oncology where he was Vice President of Marketing, Operations & Analytics which included responsibility for leading Takeda’s commercial oncology portfolio in the US which contained four compounds across various tumor types. Ryan also worked in the Global Development Division for Takeda as a Global Team Leader overseeing the development of Takeda’s prostate cancer portfolio in addition to several early stage molecules. Prior to Takeda Ryan started his career with Roche Pharmaceuticals (currently Genentech) in their commercial organization. He held positions of increasing responsibility for Roche in both the sales and marketing organizations (U.S. and Global).

Ryan received his Doctorate of Pharmacy from Purdue University. He continues his involvement with the University as a member of the Dean’s Advisory Council for the College of Pharmacy. He also serves as a board member for the MassBio Education Foundation.

Edward Driggers, PhD, Chief Technology Officer 
Edward Driggers, PhD
Chief Technology Officer

Ed is CTO at Rheos Medicines and has over 15 years of scientific and technology experience in emerging biotechnology companies.  Prior to joining Rheos, Ed created and led the Cell Metabolism Department at Agios Pharmaceuticals where he built an industry-leading platform for metabolism discovery and was a co-author of publications in Immunity, Nature, and Science which documented the discovery of 2HG production by IDH-mutant tumors that has led to the development of Idhifa and other treatments for acute myelogenous leukemia.  Prior to Agios, he held R&D roles at Ensemble Discovery and Microbia, Inc. and is a Founder and Managing Partner of General Metabolics, LLC, a boutique contract research group supporting academic and industrial researchers in metabolomics.

Ed completed a NSF-Sloan Post-Doctoral Fellow at Stanford University, studying molecular evolution.  He received his PhD in Bio-organic chemistry at the University of California, Berkeley and an SB in Biological Chemistry at the University of Chicago.

Brian Albrecht, PhD, Vice President, Drug Discovery 
Brian Albrecht, PhD
Vice President, Drug Discovery

Brian is the head of drug discovery for Rheos Medicines.  Prior to Rheos, Brian was a Principal at Third Rock Ventures where he focused on new company formation and drug discovery due diligence.  During his time at Third Rock Ventures he contributed to the launch of Fulcrum Therapeutics, Goldfinch Bio, Relay Therapeutics, Tango Therapeutics and now Rheos Medicines.  Prior to joining Third Rock, Brian built and led the medicinal chemistry department at Constellation that delivered two clinical candidates. Prior to Constellation, Brian was a member of the medicinal chemistry department at Amgen.

Brian is a co-inventor on over 30 issued patents and a co-author on more than 40 publications. Brian earned his Ph.D. in organic chemistry from Colorado State University and his B.S. in chemistry from Lafayette College.

Hozefa Bandukwala, PhD, Senior Director, Head of Discovery Biology 
Hozefa Bandukwala, PhD
Senior Director, Head of Discovery Biology

Hozefa leads the biology effort at Rheos.  Prior to joining Rheos, he was Associate Research Fellow in Pfizer’s Inflammation & Immunology Research Unit, leading discovery efforts to identify novel targets for autoimmunity. Before joining Pfizer Hozefa held a faculty position at the La Jolla Institute of Allergy and Immunology, and consulted for a biotech company CalciMedica.

Hozefa earned his PhD from the University of Chicago, where his research thesis focused on evaluating the contribution of Fc receptors in the function of dendritic cells. He completed postdoctoral training at Harvard Medical School, where he focused on the role of epigenetic regulation of genes involved in the inflammatory responses of T-cells. His research uncovered a novel link between epigenetic modification in immune cells and their ability to reprogram their metabolic pathways to meet the increased energy and biosynthetic demands required for inducing inflammatory functions.

Back to Top